MOTS-c peptide claims: what the science actually supports

What did @ahmadyasinmd actually say?

Dr. Yasin describes MOTS-c as a 16-amino-acid mitochondrial peptide that acts as an "exercise mimicure" — meaning, in his words, "you exercise without exercising." He says it may improve insulin sensitivity, reduce insulin resistance, target skeletal muscle, support weight loss, and boost mitochondrial energy production. He then provides a specific dosing protocol: 3 mg three times a week for four weeks, followed by 5 mg every five days for another four weeks, then a two-to-three-month break before cycling again. He also recommends stacking it with SS-31, 5-amino-1MQ, AOD-9604, and "maybe GEL." Side effects mentioned include water retention, fatigue, injection-site tightness, and mild blood sugar drops.

Does the science back this up?

Partially, but the gap between what early research shows in mice and what Dr. Yasin implies for human patients is large enough to matter. The "exercise mimicker" framing has some biological basis, but it is being stretched well beyond the evidence.

MOTS-c is a real peptide encoded in mitochondrial DNA and was identified by Lee et al. (2015, Cell Metabolism) as a regulator of glucose metabolism, specifically through the AMPK pathway, which overlaps with exercise-induced signaling. That study was conducted in mice and cell cultures. A 2021 follow-up by Reynolds et al. in Nature Communications found MOTS-c levels rise in humans during exercise and correlate with insulin sensitivity in older adults. That is genuinely interesting. But "correlates with" is not the same as "supplementing it reproduces exercise benefits." No large randomized controlled trials in humans have tested MOTS-c supplementation for weight loss, endurance, or insulin resistance outcomes. The "exercise without exercising" claim has no human clinical trial support at this time.

What did they get wrong (or right)?

Credit where it is due: the basic biology is described reasonably. MOTS-c does appear to influence mitochondrial metabolism and AMPK activation, and the 16-amino-acid description is accurate. The caution to consult a healthcare provider before using peptides is appropriate and worth noting.

What is wrong is the dosing protocol. Providing specific milligram doses — "3 mg three times a week" — in a public video crosses a line that educational content should not cross. There is no established human clinical dosing for MOTS-c because the compound has not completed Phase II or III trials. The doses being circulated in peptide communities are extrapolated from animal studies, not validated human pharmacokinetics. Beyond that, recommending a stack that includes 5-amino-1MQ and AOD-9604 in the same breath compounds the problem. AOD-9604 had its therapeutic goods approval withdrawn in Australia after clinical trials failed to demonstrate efficacy (Metabolic Pharmaceuticals, 2007). The claim that MOTS-c will improve your weight loss or that stacking it with these compounds is appropriate is not supported by human evidence and should have been stated more carefully.

What should you actually know?

MOTS-c is one of the more scientifically interesting peptides in early-stage research. The mitochondrial origin is unusual — most peptides are nuclear-encoded — and the AMPK connection gives researchers a plausible mechanism to study. That makes it worth watching, not worth injecting based on a TikTok protocol.

The honest summary: animal data is promising, the human correlational data from Reynolds et al. (2021) is intriguing, and that is roughly where the evidence stops. The FDA has not approved MOTS-c for any therapeutic use. Compounded versions available through peptide providers are not the same as research-grade material used in studies, and purity and dosing consistency cannot be assumed. If you are interested in metabolic health, insulin sensitivity, and mitochondrial function, there are interventions with actual human trial data: resistance training, metformin in appropriate populations, and caloric management. MOTS-c may eventually join that list. It is not there yet.